Cryo Cell International Inc

• Observed GAAP P/E is about 46.19x.
• Return on equity is about -3.4%.
• Debt to equity is about -0.0x.
• [TRIGGER] allocator_boost: allocator_boost (allocator) on CCEL — watcher=allocator; producer_version=ws49-p2a-v1; plan_date=2026-07-16; rank=24; ev=7.035464; company_id=75905260-c32d-4a52-9cec-afc8bd7f25fb; jurisdiction=US-DE; term_contributions={'event_proximity': 1.103638, 'gradability': 2.0, 'staleness': 3.931826, 'credibility_interest': 0.0}; days_since_analysis=50; pending_promises=0; reason=Allocator coverage boost rank #24 EV=7.035464 for CCEL (hot+stale; days_since=50); contributing_watchers=allocator (source=allocator; url=allocator:2026-07-16:CCEL)
• Likely peers from the same classification include JPMorgan Chase, Bank of America, Citigroup.
• AND SUBSIDIARIES CONSOLIDATED B ALANCE SHEETS (Unaudited) May 31, November 30, 2026 2025 ASSETS Current Assets Cash and cash equivalents $ 507,302 $ 319,031 Marketable securities 2,654,665 2,977,013 Accounts receivable (net of allowance for doubtful accounts of $ 4,368,665 and $ 4,306,410 , respectively) 6,910,079 6,846,180 Prepaid expenses 507,747 573,218 Inventory, current portion 310,170 408,794 Other current assets 414,391 633,985 Total current assets 11,304,354 11,758,221 Property and Equipment-net 20,668,602 21,034,372 Other Assets Intangible assets, net 840,765 863,074 Inventory, net of current portion 760,000 776,000 Goodwill 1,941,411 1,941,411 Deferred tax assets 23,620,711 23,620,711 Operating lease right-of-use asset 621,943 819,626 Deposits and other assets, net 948,644 915,099 Total other assets 28,733,474 28,935,921 Total assets $ 60,706,430 $ 61,728,514 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable $ 2,847,104 $ 2,870,771 Accrued expenses 2,967,214 4,278,027 Note payable 195,135 183,650 Line of credit - 2,300,000 Current portion of operating lease liability 421,888 430,221 Deferred revenue 9,498,548 9,730,318 Total current liabilities 15,929,889 19,792,987 Other Liabilities Deferred revenue, net of current portion 53,269,359 50,974,678 Note payable, net of current portion and debt issuance costs 8,082,030 8,170,130 Operating lease long-term liability 260,664 474,628 Long-term liability - revenue sharing agreements 875,000 875,000 Other liabilities 47,020 47,020 Total other liabilities 62,534,073 60,541,456 Total liabilities 78,463,962 80,334,443 Commitments and contingencies (Note 9) — — Stockholders' Deficit Preferred stock ($ .01 par value, 500,000 authorized and none issued and outstanding) — — Series A Junior participating preferred stock ($ .01 par value, 20,000 authorized and none issued and outstanding) — — Common stock ($ .01 par value, 20,000,000 authorized; 14,884,619 issued and 8,062,650 outstanding as of May 31, 2026 and 14,877,119 issued and 8,055,150 outstanding as of November 30, 2025) 148,846 148,771 Additional paid-in capital 44,955,224 44,708,596 Treasury stock, at cost ( 25,025,058 ) ( 25,025,058 ) Accumulated deficit ( 37,836,544 ) ( 38,438,238 ) Total stockholders' deficit ( 17,757,532 ) ( 18,605,929 ) Total liabilities and stockholders' deficit $ 60,706,430 $ 61,728,514 The accompanying notes are an integral part of these consolidated financial statements.

Bull / Bear case

Estimate revisions